Pfizer Shares Tumble 7% As Company Stops Sale Of Corex Cough Syrup

Mumbai, Mar 14 (PTI) Shares of pharmaceutical firm Pfizer today slumped nearly 7 per cent as the company discontinued the manufacture and sale of popular cough syrup Corex with immediate effect.

The stock plunged 6.94 per cent to Rs 1,794 on BSE. At NSE, shares of the company tanked 6.85 per cent to Rs 1,796.

Pfizer Shares Tumble 7% As Company Stops Sale Of Corex Cough Syrup
Pfizer: Quotes, News
BSE 1901.50BSE Quote25.15 (1.32%)
NSE 1909.20NSE Quote23.55 (1.23%)

Pfizer has discontinued manufacture and sale of Corex cough syrup with immediate effect after the government banned fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup.

"This is to inform you that the Government of India vide Notification... dated March 10, 2016... has prohibited the manufacture for sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect," Pfizer said in a BSE filing today.

In view of this, the company has discontinued the manufacture and sale of the drug with immediate effect, it said.

"The above prohibition is likely to have an adverse impact on the revenue and profitability of the company... Corex recorded sale of Rs 176 crore for the nine month period ended December 31, 2015," the company said.

PTI

Read more about: pfizer
Story first published: Monday, March 14, 2016, 13:25 [IST]
Please Wait while comments are loading...
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

Thousands of Goodreturn readers receive our evening newsletter.
Have you subscribed?